For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...

Lynparza is already the most widely-used PARP inhibitor, and the new results could help to extend its lead over rivals in the class like GSK's Zejula (niraparib), Pfizer's Talzenna (talazoparib ...

The big pharma is already a big player in the $20 billion breast cancer category, with drugs like CDK4/6 inhibitor Ibrance (palbociclib), PARP inhibitor Talzenna (talazoparib), hormonal therapy ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...